Gallstones Clinical Trial
Official title:
Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study
Verified date | December 2014 |
Source | Galmed Pharmaceuticals Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
This is a one center, Phase IIa, randomized, double blind, placebo controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects 18 to 75 years of age, with newly formed cholesterol gallstones in their gallbladder following bariatric surgery confirmed by gallbladder ultrasound ..
Status | Terminated |
Enrollment | 10 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Male or female age 18 to 75 years. 2. Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound. 3. Bariatric surgery conducted during the last 12 months 4. Patients with "sleeve gastrectomy" or laparoscopic banding of the upper stomach will be included. 5. Signature of the written informed consent. 6. Negative pregnancy test at study entry for females of child bearing potential. 7. Females of child bearing potential practicing reliable contraception throughout the study period (not including oral contraceptives). 8. Hypertensive patients must be well controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study). 9. Patients treated with vitamin E(>400IU/die), or Polyunsaturated fatty acid (>2g/d) or Ursodeoxycholic acid or fish oil can be included if drugs are stopped at least 3 months prior to study enrollment to the study and up to it end. 10. For patients with type 2 Diabetes, glycaemia must be controlled (Glycosylated Hemoglobin A1C = 8% while any HbA1C increment should not exceed 1% during 6 month prior to enrollment). If glycaemia is controlled by medications, qualitative change is not permitted within 3 months prior to randomization and should be avoided during the study. Treatments with Metformin, Sulfamides and Insulin are authorized. Sulfamides and insulin are permitted if glycaemia is self-monitored by the patient. Exclusion Criteria: 1. Patients with ultrasonography evidence of gallstones in gallbladder before having the bariatric surgery. 2. Patients with no clear ultrasonography evidence of gallstones -free gallbladder during the year prior their bariatric surgery. 3. Patients with ultrasonography evidence of gallstones more than 1 year following bariatric surgery. 4. Patients with ultrasonography evidence of gallstones in size greater than 9 mm less than 1 year following bariatric surgery. 5. Weight >140 Kg or BMI >40 6. Known alcohol and/or any other drug abuse or dependence in the last five years 7. Known history or presence of clinically significant cardiovascular, hepatic, gastrointestinal, neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder or nephritic syndrome. 8. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including bile salt metabolism (e.g. inflammatory bowel disease (IDB); previous intestinal (ileal or colonic) operation; chronic pancreatic; celiac disease or previous vagotomy 9. Uncontrolled blood pressure 10. Patients with HIV 11. Patients with renal dysfunction eGFR< 60. 12. Patients with pancreatitis, cholangitis or cholecystitis in the previous 4 months. 13. Women who are pregnant or breastfeeding 14. Type 1 Diabetes. 15. .Metformin, Fibrates, Statins, Insulin, Sulfonilurea not provided on a stable dose in the last 6 months. 16. Patients who are treated with Valproic acid, Tamoxifen, Methotreksate, Amiodaron. 17. Treatment with Rifaximin. 18. Homeopathic and/or Alternative treatments. Any treatment should be stopped before the screening period. 19. Serum creatine phosphokinase (CPK), ALT, AST and/or alkaline phosphatase >3X the upper limit of normal (ULN). Patients with an intermittent CPK elevation may have the repeated measurement prior to randomization; a CPK retest > 3X ULN leads to exclusion. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Assuta Medical Center | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Galmed Pharmaceuticals Ltd |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete dissolution of existing gallstones proven by repeated US examined gallbladder | Change from baseline measured by US scan | At baseline and week 12 | No |
Secondary | Decrease of more than a 50% in number of stones. (change from baseline) | change from baseline measured by US scan | At baseline and week 12 | No |
Secondary | Prevention of formation of new gallstones during the study period | change from baseline measured by US scan | At baseline and week 12 | No |
Secondary | Dissolution of sludge. | change from baseline measured by US scan | At baseline and week 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01625026 -
Obeticholic Acid in Bariatric and Gallstone Disease
|
Phase 2 | |
Completed |
NCT00530998 -
Minimally Invasive Surgery: Using Natural Orfices
|
||
Completed |
NCT02858986 -
3D Versus 4K Laparoscopic Cholecystectomy
|
N/A | |
Active, not recruiting |
NCT05592795 -
Explore the Effects and Mechanisms of ERCP and EST on Biliary Microecology
|
||
Completed |
NCT02469935 -
Accuracy of Surgeon-performed Ultrasound in Detecting Gallstones - a Validation Study
|
N/A | |
Withdrawn |
NCT01232959 -
Feasibility of Transvaginal Cholecystectomy
|
N/A | |
Completed |
NCT01190280 -
Indications for Gallbladder Surgery in Gallstone Disease
|
Phase 3 | |
Withdrawn |
NCT00460980 -
Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model
|
N/A | |
Completed |
NCT02344654 -
Fluorescence Cholangiography During Cholecystectomy - a RCT
|
N/A | |
Completed |
NCT00528632 -
Gallbladder Cholesterolosis, Body Mass Index and Serum Cholesterol and Triglycerides
|
N/A | |
Recruiting |
NCT03891147 -
A Clinical Trial of Electro-acupuncture for Treating Gallstone Diseases
|
N/A | |
Not yet recruiting |
NCT06385860 -
Prediction Model for Early Biliary Stasis After Bariatric Surgery
|
||
Completed |
NCT02831556 -
Point of Care 3D Ultrasound for Various Applications: A Pilot Study
|
||
Completed |
NCT02947256 -
Laparoscopic Cholecystectomy With Retro-infundibular Approach
|
Phase 2 | |
Recruiting |
NCT01438385 -
Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
|
N/A | |
Completed |
NCT01410734 -
Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree (up to 2-weeks Post-operatively)
|
N/A | |
Withdrawn |
NCT00240123 -
Effect of Benadryl Sedation During ERCP or EUS
|
Phase 1 | |
Completed |
NCT03809559 -
Repeatability and Reproducibility of Quantitative MRCP
|
||
Recruiting |
NCT01822262 -
Contrastive Study for Minimally Invasive Cholecystolithotomy With Gallbladder Reservation and Laparoscopic Cholecystectomy
|
Phase 4 | |
Active, not recruiting |
NCT03247101 -
Probiotics for Gallstones in Post-bariatric Surgery Patients:A Prospective Randomized Trial
|
N/A |